We are live on ! Find out more
PRVA icon

Privia Health

234 hedge funds and large institutions have $2.85B invested in Privia Health in 2023 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 99 increasing their positions, 44 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more call options, than puts

Call options by funds: $4.96M | Put options by funds: $1.52M

163% more first-time investments, than exits

New positions opened: 71 | Existing positions closed: 27

125% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 44

28% more capital invested

Capital invested by funds: $2.23B → $2.85B (+$619M)

24.04% more ownership

Funds ownership: 70.38%94.43% (+24%)

23% more funds holding

Funds holding: 191234 (+43)

Holders
234
Holders Change
+43
Holders Change %
+22.51%
% of All Funds
3.67%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
71
Increased
99
Reduced
44
Closed
27
Calls
$4.96M
Puts
$1.52M
Net Calls
+$3.43M
Net Calls Change
-$198K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$386M +$345M +13,072,807 +771%
BlackRock
2
BlackRock
New York
$364M +$246M +9,319,052 +202%
Vanguard Group
3
Vanguard Group
Pennsylvania
$286M +$143M +5,407,693 +98%
DCP
4
Durable Capital Partners
Maryland
$237M +$240M +9,090,909 New
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$123M +$51.7M +1,956,649 +71%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$120M +$122M +4,611,046 New
RP
7
Riverbridge Partners
Minnesota
$113M +$55.1M +2,084,802 +92%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$104M +$10.8M +408,843 +11%
Principal Financial Group
9
Principal Financial Group
Iowa
$88.6M +$28.9M +1,095,721 +48%
State Street
10
State Street
Massachusetts
$77.8M +$45.6M +1,727,559 +138%
Invesco
11
Invesco
Georgia
$43.8M +$14.6M +553,528 +49%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$42.2M +$15.3M +579,875 +56%
Franklin Resources
13
Franklin Resources
California
$31.9M -$1.03M -38,882 -3%
BG
14
Bellevue Group
Switzerland
$29.3M +$3.17M +120,000 +12%
APM
15
Avidity Partners Management
Texas
$28.2M +$28.5M +1,079,806 New
Northern Trust
16
Northern Trust
Illinois
$27.3M +$10.8M +408,307 +64%
EAM
17
Eventide Asset Management
Massachusetts
$26.1M
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$25M +$22.9M +868,709 +993%
Janus Henderson Group
19
Janus Henderson Group
United Kingdom
$23.9M -$1.65M -62,402 -6%
Norges Bank
20
Norges Bank
Norway
$22.7M +$5.95M +225,245 +35%
EA
21
Emerald Advisers
Pennsylvania
$22.4M +$815K +30,870 +4%
Alyeska Investment Group
22
Alyeska Investment Group
Illinois
$21.2M +$19.8M +748,439 +1,172%
SIG
23
Senator Investment Group
New York
$20.2M +$660K +25,000 +3%
Federated Hermes
24
Federated Hermes
Pennsylvania
$20.2M +$7.19M +272,236 +54%
EMFAT
25
Emerald Mutual Fund Advisers Trust
Pennsylvania
$18.9M +$607K +22,975 +3%

PRVA Hedge Fund Activity: Q2 2023 in Review

234 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Privia Health (PRVA) for Q2 2023, worth a combined $2.85B — up 28% from $2.23B a quarter earlier.

Buyers outnumbered sellers: 71 funds opened new PRVA positions and 27 closed out — a net gain of 44 holders — while 99 added to existing stakes and 44 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $345M. The largest seller was Goldman Sachs, cutting an estimated $655M.

  • 234 institutional investors held Privia Health (PRVA) as of Q2 2023, up from 191 in Q1 2023.
  • Funds reported $2.85B of Privia Health stock for Q2 2023, up 28% quarter-over-quarter.
  • 71 funds opened new Privia Health positions in Q2 2023 and 27 closed out, a net change of +44 holders.
  • The largest Privia Health buyer in Q2 2023 was Fidelity Investments, an estimated $345M added.
  • The largest Privia Health seller in Q2 2023 was Goldman Sachs, an estimated $655M sold.

Based on aggregated 13F filings for Q2 2023.